Mr. ZHOU Gaobo, was appointed as the chief investment officer of Simcere Pharmaceutical Group Limited on January 17, 2022. He is primarily responsible for business investment, business development management, strategic planning, affairs in Hong Kong and investor relations management. Mr. ZHOU has approximately 15 years of management consulting experience in the healthcare industry. He was a partner of McKinsey & Company from January 2014 to January 2022, and was the joint head of McKinsey’s Greater China Healthcare practice from October 2019 to January 2022. Prior to this, he had taken various positions, including consultant, engagement manager and associate partner at McKinsey between July 2006 to December 2013. He worked with leading pharmaceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in China Healthcare Reform and innovation, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development from July 2002 to July 2004. Mr. ZHOU graduated with a bachelor’s degree in genetics from Fudan University in July 2000. He obtained a master of science degree in biochemistry from the University of Maryland in July 2002, as well as a master’s degree in business administration from Duke University in May 2006.